deb00 | ACSJCA | JCA10.0.1465/W Unicode | research.3f (R3.6.i9:4386 | 2.

0 alpha 39) 2015/05/14 15:05:00 | PROD-JCAVA | rq_4776202 |

6/12/2015 12:59:11 | 11 | JCA-DEFAULT

Article
pubs.acs.org/jnp

Syntheses and in Vitro Antiplasmodial Activity of Aminoalkylated

2 Chalcones and Analogues
1

Anke Wilhelm,*, Pravin Kendrekar, Anwar E. M. Noreljaleel, Efrem T. Abay, Susan L. Bonnet,

,
4 Lubbe Wiesner, Carmen de Kock, Kenneth J. Swart, and Jan Hendrik van der Westhuizen*
3

5
6
7
8
9

10
11
12
13
14
15
16
17

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Department of Chemistry and Directorate: Research Development, University of the Free State, Nelson Mandela Drive 205,
Bloemfontein 9301, South Africa

Department of Pharmacology, University of Cape Town, Medical School, Observatory 7925, South Africa

PAREXEL International Clinical Research Organization, Private Bag X09, Brandhof 9324, Bloemfontein 339, South Africa
S Supporting Information
*

ABSTRACT: A series of readily synthesized and inexpensive aminoalkylated chalcones and diarylpropane analogues (155)
were synthesized and tested against chloroquinone-sensitive (D10 and NF54) and -resistant (Dd2 and K1) strains of Plasmodium
falciparum. Hydrogenation of the enone to a diarylpropane moiety increased antiplasmodial bioactivity signicantly. The
inuence of the structure of the amine moiety, A-ring substituents, propyl vs ethyl linker, and chloride salt formation on further
enhancing antiplasmodial activity was investigated. Several compounds have IC50 values similar to or better than chloroquine
(CQ). The most active compound (26) had an IC50 value of 0.01 M. No signs of resistance were detected, as can be expected
from compounds with structures unrelated to CQ and other currently used antimalarial drugs. Toxicity tests (in vitro CHO cell
assay) gave high SI indices.

alaria is one of the leading causes of death, and 300500

million new clinical cases and 660 000 deaths are
reported annually. Almost 90% of cases and deaths occur in
sub-Saharan Africa, where malaria is the leading cause of
morbidity of children younger than 5 years and pregnant
women.1 Despite extensive research, malaria remains a serious
threat, places a substantial strain on health services, and costs
Africa at least $12 billion in lost production annually. This is
attributed to the emergence of drug resistance by Plasmodium
falciparum, the main cause of human malaria infections.13
Artemisone, synthesized from dihydroartemisinin, is currently the only drug devoid of resistance problems. However,
disconcerting indications of resistance to artemisinin have been
reported from Southeast Asia.4,5 Owing to its short half-life (t1/2
25 h), it cannot be used as a prophylaxis and is used in
combination therapies with existing drugs to increase the halflife. These existing drugs cannot be used alone, as P. falciparum
have developed various degrees of resistance, depending on the
malaria strain and the region. Eorts to develop antimalarial
vaccines have, despite so-called promising results, failed to
produce vaccines.68 The quest thus remains to develop new
antimalarial drugs to replace those that have already partially or
fully succumbed to resistance and are expected to become
ineective.
A plethora of in vitro biological activities have been reported
for avonoids including antimicrobial,9 anti-inammatory,10
anticancer,11 and antioxidant12 properties. Many avonoidcontaining extracts, particularly bark extracts, are used tradi XXXX American Chemical Society and
American Society of Pharmacognosy

tionally to treat malaria. Chalcones (1,3-diaryl-2-propen-1ones) are precursors in the biosynthesis of avonoids and occur
widely in medicinal plants. Bioactivity of chalcones includes in
vivo activity against skin carcinogenesis13 and limiting cell
proliferation. The in vivo ecacy and mode of action of
avonoids, including chalcones, is however controversial since
polar polyphenols are poorly absorbed, do not conform to the
Lipinski rules,14 and are rapidly metabolized by liver enzymes in
the plasma,15 leading to insignicant bioavailability. It thus
remains a challenge to reconcile their poor bioavailability with
putative health eects.
Most drugs contain nitrogen, and the introduction of
nitrogen into molecules has often led to enhanced bioactivity.
Dimmock and co-workers reviewed the biological activity of
Mannich bases,16 obtained via the Mannich reaction, and found
properties such as antimalarial,17,18 antiviral,19 and antibacterial20 activity. Flavonoids have also served as scaolds and
inspiration to design new molecules with potential biological
activity. Little research has been reported on the synthesis and
biological activity of chalcones with nitrogen moieties. Reddy
and co-workers21 reported the syntheses and in vitro biological
evaluation of heterocyclic nitrogen-containing chalcones with
dierent substitution patterns in the B-ring, together with a
discussion of structureacitivity relationships. We postulated an
Received: February 4, 2015

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69

Journal of Natural Products

70
71
72
73
74
75
76
77
78
79
80
81
82
83
s1

84
85

s2

86

Article

increase in the bioactivity and ecacy of chalcones by reducing

the number of OH groups, removing the enone moiety, and
introducing a nitrogen functionality. Herein we report the
syntheses of a series of novel aminoalkylated chalcones and
analogues via the Mannich reaction and the evaluation of their
in vitro antiplasmodial bioactivity. Most of the analogues are
molecules where the enone moiety has been reduced to yield a
diarylpropane. Since the Mannich reaction with aromatic
compounds requires a hydroxy group on the aromatic ring,
the synthetic compounds are classied as -aminoalkyl
phenols.22,23

lpropanes (Scheme 4). Salient is the fact that yields of the

aminoalkylation steps of both the dihydrochalcone and
diarylpropanes were superior to those obtained upon aminoalkylation of the chalcones. The unconjugated B-ring is thus
more nucleophilic in the Mannich reaction, as removal of
conjugation probably increased the energy of the highest
occupied aromatic -orbital and, thus, nucleophilicity.
The ratio between partially and fully reduced chalcones could
be controlled by the reaction time of hydrogenation (2448 h
vs 4872 h) and the reaction conditions. Hydrogenation was
initially performed at 20 bar, but it was subsequently found that
the presence of catalytic amounts of 10% HCl(aq) gave high
yields of the fully reduced chalcone at atmospheric pressure.
The carbonyl group on chalcone-type compounds with
heterocyclic A-rings, particularly those containing nitrogen
and sulfur, e.g., compound 1618, was rather resistant to
catalytic hydrogenation. This was attributed to conjugation of
the carbonyl with the lone-pair electrons on the sulfur and
nitrogen atoms of the heterocyclic A-ring. By using Wol
Kisher reduction (NH2NH2 and KOH/NaOH)31 the target
arylpropanes with nitrogen- and sulfur-containing A-rings were
subsequently obtained.
Some aminoalkylated phenols, e.g., compounds 46 and 47
(Tables 8 and 9), were obtained from reacting phenols with
CH2O/piperidine (Scheme 5). Compounds 46 and 47 are
similar to 2-aminomethyl-3,5-di-tert-butylphenol (MK-4815)
(Figure 1), which has been investigated by Merck Research
Laboratories as a potential treatment for malaria.32 The
diarylethane analogue 49 was synthesized via the sequence
depicted in Scheme 7, using the Wittig reaction for the
formation of the 1,2-diarylethene functionality.
Structure Elucidation. E-Chalcones are characterized by
the large J, (trans) 1H NMR coupling constants of 1516 Hz
in the aromatic region. These change to two two-proton triplets
(J = 7 Hz) at about 3.24 and 2.96 ppm in the aliphatic region
upon hydrogenation to form the dihydrochalcones. The
diarylpropanes exhibit two two-proton triplets (J = 7 Hz) at
about 2.49 and 2.55 ppm and a two-proton multiplet at about
1.85 ppm. Salient in the aminoalkylated chalcones and
diarylpropanes is the benzylic aminomethylene moiety that
resonates as a two-proton singlet at about 3.60 ppm. The
heterocyclic amine substituents often require elevated temperatures for well-resolved resonances. This is attributed to
hydrogen bonding between nitrogen and the o-hydroxy
function that restricts rotation via the presence of a sixmembered ring. Ortho-aminoalkylated produts were observed
in this study. The o-aminoalkylated product is probably
stabilized by the aforementioned hydrogen bond. This explains
the exclusive formation of o-substituted products under mild
reaction conditions (Scheme 2). Para-substitution was observed
in only one case subsequent to ortho-substitution to yield an
o,p-diaminoalkylated product. This, however, required extended
reaction times.
From the HMBC data (compound 24, used as an example),
H-3 correlates with both C-2 and C-6. The aminomethylene
protons (N-CH2) correlate with C-3, C-4, and C-5. The

RESULTS AND DISCUSSION

Chemistry. The amino functionality was introduced with
the Mannich reaction into a series of chalcones, available via the
aldol reaction (Scheme 1). The Mannich reaction can be
applied to aromatic rings provided one hydroxy group is
available in the ortho-position (Scheme 2).
Scheme 1. Synthesis of Aminoalkylated Chalcones

Scheme 2. Aminomethylation of Phenols via the Mannich

Reaction

87
88
89
90
91
92
93
94
95
96
97
98
99
100
s3

101
102
103
104

s4

105

It is well known that aromatic OH groups are the targets for

enzymatic removal of phenols from plasma, via either
degradation or conjugation. 2426 The enoyl moiety is
associated with toxicity via conjugated nucleophilic attack
with DNA and consequent alkylation.27 Enone moieties are
rigid compared to their propane counterparts and would not t
as readily into enzyme active sites.2830 Medicinal chemistry
considerations thus suggest that changing the enoyl moiety into
a propane moiety and removal of aromatic OH groups would
enhance the ecacy and bioavailability and reduce toxicity of
chalcones and aminoalkylated chalcones.
Hydrogenation of the aminoalkylated chalcones gave the
corresponding propanes in poor yields (510%), and products
where the benzylic aminoalkyl groups had been lost were
isolated (Scheme 3). The chalcones were subsequently
hydrogenated prior to performing the Mannich aminoalkylation
reaction to secure high yields for both the hydrogenation and
aminoalkylation steps. Yields ranged between 80% and 90% for
the dihydrochalcones and in excess of 90% for the diaryScheme 3. Hydrogenation of Aminoalkylated Chalcones

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

106 s4
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129 t1
130 s5
131
132 f1
133
134
135 s6s7
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161

t9

Journal of Natural Products

Article

Scheme 4. Synthesis of Dihydrochalcones and Diarylpropanes Followed by Mannich Aminoalkylation

Table 1. 1H NMR (600 MHz) Data for Compounds 1 (Acetone-d6), 3 (Acetone-d6), 20 (CDCl3), 23 (CDCl3), and 24 (CDCl3)
[H, ppm, Mult. (J in Hz)]
proton
H-1
H-2
H-3
H-2/6
H-3/5
H-2
H-3
H-4
H-5
H-6
H-2/6
H-3/5
H-4
OCH3
CH2
a

20

H (J in Hz)

H (J in Hz)

H (J in Hz)

7.69, d (15.6)
7.80, d (15.6)
8.16, d (8.9)
7.07, d (8.9)
7.307.25,a m

7.68,
7.81,
8.18,
7.07,
7.17,

7.307.25,a m
7.307.25,a m
6.956.93,a m

b3

(15.5)
(15.5)
(8.9)
(8.9)
(1.5)

7.09, d (7.5)
7.16, dd (7.5, 1.5)
2.53, br s
1.661.60, m
1.52, br s
3.91, s
3.74, s

3.91, s

Interchangeable.

d
d
d
d
d

d (7.5)
dd (7.6, 1.5)
br s
s
s

6.72, d (7.6)
7.10, t (8.0)
6.64, d (1.5)

24
H (J in Hz)
2.56, t (7.6)
1.911.82, m
2.53, t (7.6)
7.10, d (8.7)
6.82, d (8.7)
6.56, d (1.5)

6.86,
6.86,
2.45,
1.57,
1.46,
3.73,
3.59,

d (7.2)
dd (7.3, 1.5)
br s
p
br s
s
s

JHH. c4JHF.

20

23

24

carbon

C-1
C-2
C-3
C-1
C-2
C-3
C-4
C-5
C-6
C-1
C-2
C-3
C-4
C-5
OCH3
CH2
C-2
C-3
C-4
C-5
C-6

187.4
121.9
143.3
131.1
130.7
113.9
163.6
113.9
130.7
136.7
117.4
157.8
114.9
129.9
55.1

188.2
122.3
144.1
132.1
131.6
114.7
164.5
114.7
131.6
136.5
120.7
159.6
125.6
130.0
56.0
62.4
54.5
26.7
24.6
26.7
54.4

197.8
40.3
30.0
133.3a (3.1)
130.7b (9.1)
115.7c (21.8)
165.7d (254.4)
115.7c (21.8)
130.7b (9.1)
141.7
115.8
158.1
119.5
128.6

34.4
32.9
35.2
134.5
129.3
113.7
157.5
113.7
129.3
144.3
115.4
155.6
112.7
129.4
55.3

35.2
34.2
35.8
135.0
130.1
114.5
159.0
114.5
130.1
143.7
116.4
26.7
24.7
26.7
54.4
62.3
55.4
26.7
24.7
26.7
55.1

b3

6.86,
6.64,
2.47,
1.61,
1.61,

H (J in Hz)
2.572.51, m
1.891.83, m
2.572.51, m
7.06, d (8.5)
6.82, d (8.6)
6.64, d (1.5)

3.76, s

JCF.

t (7.6)
t (7.6)
dd (8.9,b 5.4,c)
t (8.9,b 8.9c)
d (1.5)

3.62, s

Table 2. 13C NMR (150 MHz) Data for Compounds 1

(Acetone-d6), 3 (Acetone-d6), 20 (CDCl3), 23 (CDCl3), and
24 (CDCl3) [C, ppm]

a4

3.24,
2.96,
7.97,
7.09,
6.69,

23

61.9
53.9
25.9
24.0
25.9
53.9

correlation between the aminomethylene protons and C-3

conrms o-substitution relative to the phenolic hydroxy group.
Biological Evaluations. Initial results for compounds 1
11 indicated that the introduction of an aminoalkyl group into
chalcones enhanced bioactivity against the chloroquinesensitive Plasmodium falciparum strain, D1033 (ca. 10-fold),
supporting our hypothesis that introduction of a nitrogen
moiety would enhance bioactivity. Replacing the piperidine
moiety with morpholine (6), 1-methylpiperazine (7), pyrrolidine (8), and 1-ethylpiperazine (9) did not increase bioactivity
signicantly. Thus, only analogues with piperidine as the amino
moiety were synthesized.
Structural modications to the A-ring indicate that A-ring
substituents have the potential to further enhance bioactivity
(Table 4). Replacing the 4-methoxy group with CF3 (12), Br
(13), CH2CH3 (14), and F (15) led to a ca. 100-fold increase
in activity. The chloroquine-resistant P. falciparum Dd234 gave
similar results to the chloroquine sensitive D10 strains with
1214. This suggests that aminoalkylated chalcones use a
dierent parasite inhibitory mechanism than chloroquine,
which usually has an RI value of between 5 and 10. Since
dihydrochalcones 2022 (Table 4) did not show increased
bioactivity compared to the chalcone precursors, no further
dihydrochalcone analogues were synthesized.
The best bioactivities were obtained with the fully reduced
diarylpropanes (Table 5, 2332), where the rigidity associated
with the planar conjugated enone was removed. This correlated
with the nding of Lovering and co-workers29 that molecules
with a higher degree of saturation and more stereogenic centers
have lower melting points, higher solubility, and a better chance

JCF. c1JCF. d(2JCF)

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

162
163 f2
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191

Journal of Natural Products

Article

Table 3. Antiplasmodial Activity (IC50) of Aminoalkylated Chalcones (311) Compared with Chalcones Devoid of a Nitrogen
Functionality (1, 2)

192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226

Data shown as means SD where applicable. bD10: chloroquine-sensitive Plasmodium falciparum strain.

of clinical success. The chloroquine-resistant strain Dd2 was

replaced with the K135 strain in Table 3. Similar to the sensitive
strains D10 and NF54,36 there are only minor genetic
dierences between Dd2 and K1, but the results are considered
similar.37
The inuence of the structure of the amine moiety on
antiplasmodial activity (Table 6) correlates with the results
obtained with aminoalkylated chalcones (Tables 3 and 4). In
the case of diarylpropanes, the pyrrolidine moiety as in 37
enhances activity slightly more than the piperidine unit as in 33.
To improve solubility in the solvents required by the in vitro
bioactivity assays and future bioanalytical quantications, Nhydrochlorides were synthesized. Bubbling dry HCl gas
through a solution of the free amine containing aminoalkylated
compounds (Table 7, 4044) in dry DCM gave the salts as
precipitates. Salt formation does not interfere with the in vitro
bioactivity and in fact enhances it for most of the compounds
tested (Table 7).
The bioactivity of a small number of diverse related
analogues (Table 8) may be useful to direct future research.
Aminoalkylphenols have been reported to have antiplasmodial
properties.32 However, removal of the arylpropane moiety,
derived from the chalcone A-ring, led to much reduced
antiplasmodial activity. A larger moiety on the A-ring (50, 53)
and shortening of the propyl to an ethyl linker (49) seem to
enhance bioactivity, while esterication (54) or removal of the
aromatic o-hydroxy group (52 compared to 39) reduces
bioactivity considerably. Compound 53, which has two
aminoalkylphenol moieties, shows good bioactivity.
The toxicity of a representative sample of the synthetic
compounds was determined with the CHO bioassay, and the
selectivity indices (SI) were calculated (Table 9). The most
active compounds showed relatively low CHO cytotoxicity and
relatively high SI values, indicating that these compounds
selectively inhibit malaria parasites compared to healthy cells.

The unreduced aminoalkylated chalcones have much lower SI

values.
In conclusion, it was established that chalcones with an
aminoalkyl moiety on the aromatic B-ring exhibit promising in
vitro antiplasmodial activity. This supports the hypothesis that
nitrogen-containing avonoids would enhance biological
activity compared to naturally occurring non-nitrogen analogues. Reduction of the enone moiety increased antimalarial
bioactivity signicantly. The structure of the amino moiety, Aring substituents, shortening of the propyl to an ethyl linkage,
and chloride salt formation further enhanced antiplasmodial
activity. The most active compound (26) has an IC50 value of
0.01 M (10 nM). Many of the compounds have similar or
better IC50 values than CQ against CQ-sensitive malaria strains
(D10 and NF54) and showed little dierence in activity against
CQ-resistant strains (Dd2 and K1). This is to be expected since
the new synthetic compounds possess structures unrelated to
CQ and other currently used antimalarial drugs. In vitro
cytotoxicity tests suggest that the compounds are relatively
nontoxic with high SI indices. Thus, we succeeded in
synthesizing antiplasmodial compounds that are relatively
uncomplicated and inexpensive to manufacture and are
structurally unrelated to existing antimalarial drugs.

EXPERIMENTAL SECTION

228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250

General Experimental Procedures. Melting points were

determined with a Reichert Thermopan microscope with a Koer
hot-stage and are uncorrected. Solid-state FT-IR spectra were recorded
as neat compound on a Bruker Tensor 27 spectrometer. A 600 MHz
Bruker Avance spectrometer was used to record the 1H NMR, COSY,
HMBC, HMQC (600 MHz) and 13C, APT (150 MHz) experiments
in either CDCl3 (H = 7.24; C = 77.2), acetone-d6, (H = 2.04; C =
29.8), or methanol-d4, (H = 4.87 and 3.31; C = 49.2) with TMS as
internal standard. Chemical shifts were expressed as parts per million
(ppm) on the delta () scale, and coupling constants (J) are accurate
to 0.01 Hz. High-resolution mass spectral data (HRMS) were
collected using a Waters Micromass LCT Premier TOF-MS
D

227

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

251
252
253
254
255
256
257
258
259
260
261
262

Journal of Natural Products

Article

Table 4. Antiplasmodial Activity of A-Ring-Substituted Chalcones (1219) and Dihydrochalcones (2022)

NF54: alternative chloroquine-sensitive Plasmodium falciparum strain. bDd2: chloroquine-resistant Plasmodium falciparum strain. cRI: resistance
index: IC50(Dd2)/IC50(D10). dND: not determined.
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286

spectrometer. All samples were dissolved and diluted to 2 ng/L and

infused without additives. Thin-layer chromatography (TLC) was
performed on Merck aluminum sheets (silica gel 60 F254, 0.25 mm).
Reactions were monitored by TLC on silica gel, with detection by UV
light (254 nm). Thin-layer chromatograms were sprayed with a 2% (v/
v) solution of formaldehyde (40% solution in H2O) in concentrated
H2SO4 and subsequently heated to 110 C to eect maximum
development of color. Purity was measured with Shimadzu HPLC
systems using a Phenomenex C18 (100 mm 4.6 mm) 2.6 m
column; 2.0 L injection volume; ow, 0.2 mL/min; isocratic system,
mobile phase A, 0.1% HCO2H in H2O, and mobile phase B, MeCN,
with a Shimadzu LC-20AD pump SPD-M20A UV detector set at 254
nm. Chemicals purchased from commercial vendors were used without
purication.
General Procedure for the Synthesis of Chalcones via Aldol
Condensation. A mixture of acetophenone (1 equiv) and aryl
aldehyde (1 equiv) was stirred in EtOH (50 mL) at room temperature.
A KOH solution (50%, 25 mL) was added after 10 min, which turned
the reaction mixture bright yellow. The reaction mixture was left to stir
overnight, after which it was quenched with ice-cold 1 N HCl (100
mL) solution and extracted with EtOAc (2 50 mL). The organic
layer was washed with water (1 50 mL) and dried over Na2SO4, and
the solvent evaporated under reduced pressure. This is demonstrated
for the synthesis of (E)-3-(3-hydroxyphenyl)-1-(4-methoxyphenyl)-

prop-2-en-1-one (1) using 4-methoxyacetophenone (3.1356 g; 20.9

mmol) and 3-hydroxybenzaldehyde (3.0547 g; 25.0 mmol).
(E)-3-(3-Hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
(1): yellow crystals38 (EtOH); mp 163164 C; IR (neat) max
3323.24, 1583.50, 1168.39, 830.84, 666.33 cm1; 1H NMR (acetoned6, TMS, 600 MHz) 8.16 (2H, d, J = 8.9 Hz, H-2, H-6), 7.80 (1H,
d, J = 15.6 Hz, H-3), 7.69 (1H, d, J = 15.6 Hz, H-2), 7.307.25 and
6.956.93 (4H, m, H-5, H-2, H-6, H-4), 7.07 (2H, d, J = 8.9 Hz,
H-3, H-5), 3.91 (3H, s, OCH3); 13C NMR (acetone-d6, TMS, 150
MHz) 187.4 (C-1), 163.6 (C-4), 157.8 (C-3), 143.3 (C-3), 136.7
(C-1), 131.1 (C-1), 130.7 (C-2, C-6), 129.9 (C-5), 121.9 (C-2),
120.0 (C-6), 117.4 (C-2), 114.9 (C-4), 113.9 (C-3, C-5), 55.1
(OCH3); HRESMS [M + H]+ m/z 255.1965 (calcd for C16H14O3 +
H+, 255.1960); Rf = 0.37, toluene/acetone (5:5), 3.506 g, 66%.
General Procedure for the Synthesis of Aminoalkylated
Chalcones via the Mannich Reaction. A mixture of the appropriate
chalcone (1 equiv), paraformaldehyde (1.5 equiv), and the appropriate
amine (2 equiv) was dissolved in EtOH (2 mL) and concentrated HCl
(5 drops). The reaction mixture was reuxed for about 9 h until TLC
showed the disappearance of the starting material. The reaction
mixture was quenched with solid NaHCO3 and extracted with EtOAc
(2 50 mL), and the extract washed with water (2 50 mL). The
organic layer was dried over Na2SO4, and the solvent evaporated under
reduced pressure. This is demonstrated for the synthesis of (E)-3-[3E

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310

Journal of Natural Products

Article

Table 5. Antiplasmodial Activity of Aminolalkylated Diarylpropanes (2332)

311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337

ltered through silica gel, and the ltrate was extracted with EtOAc (2
50 mL) and washed with water (1 30 mL) and brine (1 20 mL).
The organic layer was dried over anhydrous MgSO4, and the solvent
evaporated under reduced pressure. Column chromatography
[hexanes/EtOAc (7:3), 1.5 cm 15 cm] yielded the pure
dihydrochalcones in good yield. This is demonstrated for the synthesis
of 1-(4-uorophenyl)-3-[3-hydroxy-4-(piperidin-1-ylmethyl)phenyl]propan-1-one (20) using 1-(4-uorophenyl)-3-(3-hydroxyphenyl)propan-1-one (0.100 g; 0.41 mmol), paraformaldehyde (0.024 g;
0.80 mmol), and piperidine (0.09 mL; 0.88 mmol).
1-(4-Fluorophenyl)-3-(3-hydroxy-4-(piperidin-1-ylmethyl)phenyl)propan-1-one (20): light yellow oil; 1H NMR (CDCl3, TMS, 600
MHz) 7.97 (2H, dd, 3JHH = 8.9 Hz; 4JHF = 5.4 Hz, H-2, H-6),
7.09 (2H, t, 3JHH = 8.9 Hz; 4JHF = 8.9 Hz, H-3, H-5), 6.86 (1H, d, J
= 7.6 Hz, H-5), 6.69 (1H, d, J = 1.5 Hz, H-2), 6.64 (1H, dd, J = 7.6,
1.5 Hz, H-6), 3.62 (2H, s, CH2), 3.24 (2H, t, J = 7.6 Hz, H-2), 2.96
(2H, t, J = 7.6 Hz, H-3), 2.47 (4H, H-2, H-6), 1.61 (6H, s, H-3,
H-4, H-5); 13C NMR (CDCl3, TMS, 150 MHz) 197.8 (C-1),
165.7 (1C, d, 1JCF = 254.4 Hz, C-4), 158.1 (C-3), 141.7 (C-1),
133.3 (1C, d, 4JCF = 3.1 Hz, C-1), 130.7 (2C, d, 3JCF = 9.1 Hz, C-2,
C-6), 128.6 (C-5), 119.5 (C-4), 119.0 (C-6), 115.8 (C-2), 115.7
(2C, d, 2JCF = 21.8 Hz, C-3, C-5), 61.9 (CH2), 53.9 (C-2, C-6),
40.3 (C-2), 30.0 (C-3), 25.9 (C-3, C-5), 24.0 (C-4); column
chromatography [hexanes/EtOAc (6:4), 1.5 cm 15 cm]; Rf = 0.52;
0.118 g; 84%.
General Procedure for the Synthesis of the Diarylpropanes.
The appropriate chalcone (1 equiv) was dissolved in a 1:3 (v/v)

hydroxy-4-(piperidin-1-ylmethyl)phenyl]-1-(4-methoxyphenyl)prop2-en-1-one (3) using (E)-3-(3-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (1) (0.609 g; 2.4 mmol), paraformaldehyde (0.145 g;
4.8 mmol), and piperidine (0.50 mL; 5.1 mmol).
(E)-3-(3-Hydroxy-4-[piperidin-1-ylmethyl)phenyl]-1-(4methoxyphenyl)prop-2-en-1-one (3): beige crystals39 (EtOH); mp
120121 C; IR (KBr) max 2945.44, 2159.13, 2031.94, 1598.90,
1256.25 cm1; 1H NMR (acetone-d6, TMS, 600 MHz) 8.18 (2H, d, J
= 8.9 Hz, H-2, H-6), 7.81 (1H, d, J = 15.5 Hz, H-3), 7.68 (1H, d, J =
15.5 Hz, H-2), 7.17 (1H, d, J = 1.5 Hz, H-2), 7.16 (1H, dd, J = 7.5,
1.5 Hz, H-6), 7.09 (1H, d, J = 7.5 Hz, H-5), 7.07 (2H, d, J = 8.9 Hz,
H-3, H-5), 3.91 (3H, s, OCH3), 3.74 (2H, s, CH2), 2.53 (4H, br s, H2, H-6), 1.661.60 (4H, m, H-3, H-5), 1.52 (2H, br s, H-4);
13
C NMR (acetone-d6, TMS, 150 MHz) 188.2 (C-1), 164.5 (C-4),
159.6 (C-3), 144.1 (C-3), 136.5 (C-1), 132.1 (C-1), 131.6 (C-2,
C-6), 130.0 (C-5), 125.6 (C-4), 122.3 (C-2), 120.7 (C-2), 115.6
(C-6), 114.7 (C-3, C-5), 62.4 (CH2), 56.0 (OCH3), 54.5 (C-2, C6), 26.7 (C-3, C-5), 24.6 (C-4); HREIMS m/z 351.1826 (calcd
for C22H25NO3, 351.1824); HPLC purity 99.1%, tR = 1.54 min;
column chromatography [toluene/acetone (5:5), 1.5 cm 20 cm]; Rf
= 0.42; 0.520 g, 62%.
General Procedure for the Synthesis of the Dihydrochalcones. The appropriate chalcone (1 equiv) was dissolved in a 1:3 (v/
v) solution of EtOAc/H2O. Pd(OH)2/C (0.060 g) was added, and the
system ushed with hydrogen. The reaction mixture was left to stir at
room temperature for 2448 h under H2 at atmospheric pressure.
After completion of the reaction (TLC) the reaction mixture was
F

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364

Journal of Natural Products

Article

Table 6. Antiplasmodial Activity of Diarylpropanes with Dierent Amine Moieties (3339)

Table 7. Antiplasmodial Activity of Diarylpropane HCl Salts (4044)

365
366
367
368
369
370
371
372
373
374
375

solution of EtOAc/H2O. Ten percent HCl(aq) (10 mL) with

Pd(OH)2/C (0.060 g) was added, and the system ushed with
hydrogen. The reaction mixture was left to stir at room temperature
for 4872 h under H2 at atmospheric pressure. After completion of
the reaction (TLC) the reaction mixture was ltered through silica gel,
and the ltrate was extracted with EtOAc (2 50 mL) and washed
with water (1 30 mL) and brine (1 20 mL). The organic layer was
dried over anhydrous MgSO4, and the solvent evaporated under
reduced pressure. Column chromatography [hexanes/EtOAc (7:3),
1.5 cm 20 cm] yielded the pure diarylpropanes in good yield. This is
demonstrated for the synthesis of 3-[3-(4-methoxyphenyl)propyl]-

phenol (23) using (E)-3-(3-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (1) (0.200 g; 0.80 mmol).

3-[3-(4-Methoxyphenyl)propyl]phenol (23): yellow oil; IR (KBr)
max 2933.38, 1586.44, 1510.27, 1241.05 cm1; 1H NMR (CDCl3,
TMS, 600 MHz) 7.10 (1H, t, J = 8.0 Hz, H-5), 7.06 (2H, d, J = 8.5,
H-2, H-6), 6.82 (2H, d, J = 8.6 Hz, H-3, H-5), 6.72 (1H, d, J = 7.6
Hz, H-4), 6.64 (2H, d, J = 1.5 Hz, H-2, H-6), 3.76 (3H, s, OCH3),
2.572.51 (4H, m, H-1, H-3), 1.891.83 (2H, m, H-2); 13C NMR
(CDCl3, TMS, 150 MHz) 157.5 (C-4), 155.6 (C-3), 144.3 (C-1),
134.5 (C-1), 129.4 (C-5), 129.3 (C-2, C-6), 120.8 (C-6), 115.4
(C-2), 113.7 (C-3, C-5), 112.7 (C-4), 55.3 (OCH3), 35.2 (C-3),
G

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

376
377
378
379
380
381
382
383
384
385
386

Journal of Natural Products

Article

Table 8. Antiplasmodial Activity of Diverse Analogues (4555)

387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411

34.4 (C-1), 32.9 (C-2); HREIMS m/z 242.1306 (calcd for C16H18O2,
242.1307); Rf = 0.55, 0.185 g; 97%.
General Procedure for the Synthesis of Aminoalkylated
Diarylpropanes. A mixture of the appropriate diarylpropane (1
equiv), paraformaldehyde (1.5 equiv), and the appropriate amine (2
equiv) was dissolved in EtOH (2 mL) and concentrated HCl (5
drops). The reaction mixture was reuxed for 9 h until TLC showed
the disappearance of the starting material. The reaction mixture was
quenched with solid NaHCO3 and extracted with EtOAc (2 50 mL),
and the extract was washed with water (2 50 mL). The organic layer
was dried over Na2SO4, and the solvent evaporated under reduced
pressure. This is demonstrated for the synthesis of 5-[3-(4methoxyphenyl)propyl]-2-(piperidin-1-ylmethyl)phenol (24) using
3-[3-(4-methoxyphenyl)propyl]phenol (23) (0.165 g; 0.68 mmol),
paraformaldehyde (0.037 g; 1.23 mmol), and piperidine (0.1 mL; 1.0
mmol).
5-[3-(4-Methoxyphenyl)propyl]-2-(piperidin-1-ylmethyl)phenol
(24): light yellow oil; IR (KBr) max 2932.41, 2360.34, 1510.49,
1242.60 cm1; 1H NMR (acetone-d6, TMS, 600 MHz) 7.10 (2H, d, J
= 8.7 Hz, H-2, H-6), 6.86 (1H, d, J = 7.2 Hz, H-5), 6.82 (2H, d, J =
8.7 Hz, H-3, H-5), 6.586.54 (1H, d, J = 1.5 Hz, H-2, 1H, dd, J =
7.3, 1.5 Hz, H-6), 3.73 (3H, s, OCH3), 3.59 (2H, s, CH2), 2.56 (2H,
t, J = 7.6 Hz, H-1), 2.53 (2H, t, J = 7.6 Hz, H-3), 2.45 (4H, br s, H-2,
H-6), 1.911.82 (2H, m, H-2), 1.57 (4H, p, H-3, H-5), 1.46 (2H,
br s, H-4); 13C NMR (acetone-d6, TMS, 150 MHz) 159.0 (C-4),

158.8 (C-3), 143.7 (C-1), 135.0 (C-1), 130.1 (C-2, C-6), 129.3
(C-5), 120.0 (C-4), 119.6 (C-6), 116.4 (C-2), 114.5 (C-3, C-5),
62.3 (CH2), 55.4 (C-2, C-6), 54.4 (OCH3), 35.8 (C-3), 35.2 (C-1),
34.2 (C-2), 26.7 (C-3, C-5), 24.7 (C-4); HREIMS m/z 339.2198
(calcd for C22H29NO2, 339.2200); ash column chromatography
[hexanes/EtOAc (6:4), 1.5 cm 15 cm]; Rf = 0.52; 0.095 g; 41%.
General Synthesis of HCl Salts of the Aminoalkylated
Diarylpropanes. The appropriate aminoalkyldiarylpropane was
dissolved in dry DCM (10 mL) at 0 C. HCl gas was bubbled
through the reaction mixture for 60 min. Precipitation indicated the
formation of the salt. The excess solvent was removed under a stream
of N2 gas, and the product was lyophilized overnight. This is
demonstrated for the synthesis of 1-[2-hydroxy-4-{3-(4methoxyphenyl)propyl}benzyl]piperidinium chloride (40) using 5[3-(4-methoxyphenyl)propyl]-2-(piperidin-1-ylmethyl)phenol (26)
(0.200 g, 0.59 mmol).
1-[2-Hydroxy-4-{3-(4-methoxyphenyl)propyl}benzyl]piperidinium
chloride (40): white, amorphous solid; IR (neat) max 2935.94,
1511.06, 1242.36, 1033.16, 827.06 cm1; 1H NMR (acetone-d6, TMS,
600 MHz) 7.47 (1H, d, J = 7.8 Hz, H-5), 7.13 (2H, d, J = 8.6 Hz,
H-2, H-6), 6.98 (1H, d, J = 1.2 Hz, H-2), 6.84 (2H, d, J = 8.6 Hz, H3, H-5), 6.76 (1H, dd, J = 7.6, 1.5 Hz, H-6), 4.18 (2H, d, J = 4.7 Hz,
CH2), 3.76 (3H, s, OCH3), 3.42 (2H, d, J = 11.6 Hz, H-2), 2.96
2.87 (6H, m, H-3, H-4, H-5), 2.632.53 (4H, m, H-1, H-3),
1.941.85 (2H, m, H-2, H-6), 1.82 (2H, d, J = 14.5 Hz, H-6); 13C
H

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436

Journal of Natural Products

Article

Table 9. Toxicity Values (IC50) of the Most Promising Analogues against CHO Cell Lines and SI Values

SI: selectivity index = IC50(CHO)/IC50(D10).

Scheme 5. Synthesis of Compound 46 via the Mannich

Reaction

Figure 1. Stucture of MK-4815.

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

Journal of Natural Products

Article

Scheme 6. Synthesis of Compound 47 via the Mannich Reaction

concentration of solvent (0.5%) to which the cells were exposed had

no measurable eect on the cell viability (data not shown).

Scheme 7. Synthesis of Compound 49 via the Wittig

Reaction

ASSOCIATED CONTENT

473

S Supporting Information
*

474

Experimental detail, 1D and 2D NMR data, MS, IR, melting

points, and HPLC data. The Supporting Information is
available free of charge on the ACS Publications website at
DOI: 10.1021/acs.jnatprod.5b00114.

AUTHOR INFORMATION

*Tel: +27 (0)51 401 9305. Fax: +27 (0)51 401 7295. E-mail:
wilhelma@ufs.ac.za (A. Wilhelm).
*Tel: +27 (0)51 401 2782. Fax: +27 (0)51 401 7295. E-mail:
vdwestjh@ufs.ac.za (J. H. van der Westhuizen).

478

480
481
482
483
484

486

REFERENCES

487
488
489
490
491
492

(1) World Health Organizations Media Centre. Malaria Fact Sheet

No. 94; April 2012, Retrieved Dec 18, 2012, from http://www.who.
int/.
(2) Vitoria, M.; Granich, R.; Gilks, C. F.; Gunneberg, C.; Hosseini,
M.; Were, W.; Raviglione, M.; De Cock, K. M. Am. J. Clin. Pathol.
2009, 131, 844848.
(3) Millennium Project. Global Burden of Malaria; Retrieved Dec 18,
2012, from http://www.unmillenniumproject.org/documents/
GlobalBurdenofMalaria.pdf.
(4) World Health Organization. Global Plan for Artemisinin Resistance
Containment; 2011; p 5.
(5) Wiwanitkit, V. Malaria Research in Southeast Asia; Nova Science
Publishers, Inc.: New York, 2007; pp 311.
(6) Al-Hussaieny, N. H. Parasitol. United J. 2010, 3, 18.
(7) Gregory, G. A.; Mayfield, S. P. Appl. Microbiol. Biotechnol. 2014,
98, 19831990.
(8) Sheehy, S. H.; Douglas, A. D.; Draper, S. J. Hum. Vaccines
Immunother. 2013, 9, 18311840.
(9) Cushnie, T. P. T.; Lamb, A. J. Int. J. Microb. Agents 2011, 38, 99
107.
(10) Yamamoto, Y.; Gaynor, R. B. J. Clin. Invest. 2001, 107, 135142.
(11) De Sousa, R. R.; Queiroz, K. C.; Souza, A. C.; Gurgueira, S. A.;
Augusto, A. C.; Miranda, M. A.; Peppelenbosch, M. P.; Ferreira, C. V.;
Aoyama, H. J. Enzyme Inhib. Med. Chem. 2007, 22, 439444.
(12) Pietta, P.-G. J. Nat. Prod. 2000, 63, 10351042.
(13) Statomi, Y. Int. J. Cancer 1993, 55, 506514.
(14) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv.
Drug Delivery Rev. 2001, 46, 326.
(15) Walle, T. Free Radical Biol. Med. 2004, 36, 829837.
(16) Dimmock, J. R.; Kumar, P. Curr. Med. Chem. 1997, 4, 1.
(17) Barlin, G. B.; Jiravinya, C.; Yan, J. H. Aust. J. Chem. 1991, 44,
677685.
J

477

485

ACKNOWLEDGMENTS
We thank Dr. C. Edlin, previously from iThemba Pharmaceuticals, for his valuable input toward the structural modications
of compounds in this study. Financial support by the University
of the Free State is acknowledged.

NMR (acetone-d6, TMS, 150 MHz) 158.9 (C-4), 157.8 (C-3),

147.0 (C-1), 134.9 (C-1), 134.7 (C-2, C-6), 130.1 (C-5), 121.3
(C-6), 119.3 (C-4), 115.7 (C-2), 114.5 (C-3, C-5), 55.4 (C-2,
C-6), 52.7 (OCH3, CH2), 35.8 (C-3), 35.1 (C-1), 34.0 (C-2), 23.5
(C-3, C-5), 22.7 (C-4); HRTOFESMS [M + H]+ m/z 340.2270
(calcd C22H29NO2 + H+, 340.2277); HPLC purity 86.7%, tR = 1.61
min; 0.185 g; 84%.
Bioassays. Antiplasmodial Assay. Continuous in vitro cultures of
asexual erythrocyte stages of P. falciparum were maintained using the
modied method of Trager and Jensen.40 Quantitative assessment of
antiplasmodial activity in vitro was determined via the parasite lactate
dehydrogenase assay using a modied method described by Makler.41
The test samples were tested in triplicate on one or two separate
occasions. Compounds were initially screened for antiplasmodial
activity against the chloroquine-sensitive (CQS) D10 and NF54
strains. The most promising compounds were subsequently tested
against the chloroquine-resistant (CQR) strains, Dd2 and K1.
CQ was used as an internal standard to monitor the experimental
conditions and showed IC50 values within an acceptable range of
0.0180.060 M for the CQS strains and 0.4700.780 M for the
CQR strains. The 50% inhibitory concentration (IC50) values were
obtained from full doseresponse curves (Supporting Information),
using a nonlinear doseresponse curve-tting analysis via GraphPad
Prism v.4 software.
Cytotoxicity Assay. The MTT assay as described by Mosmann
(with minor modications) was used to determine cell viability using
the Chinese hamster ovarian (CHO) cell line.42 The sample
preparation was done in the same manner as for the antiplasmodial
testing. Emetine was used as the reference drug in all experiments and
showed IC50 values within an acceptable range (0.0800.120 M).
The initial concentration of emetine was 100 g/mL, which was
serially diluted in complete medium with 10-fold dilutions to give six
concentrations, the lowest being 0.001 g/mL. The same dilution
technique was applied to all the test samples. The highest

476

Notes

The authors declare no competing nancial interest.

437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470

475

479

Corresponding Authors

Figure 2. Selected HMBC correlations of compound 24.

471
472

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX

493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524

Journal of Natural Products

525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570

Article

(18) Barlin, G. B.; Jiravinya, C. Aust. J. Chem. 1990, 43, 11751181.

(19) Edwards, M. L.; Ritter, H. W.; Stemerick, D. M.; Stewart, K. T. J.
Med. Chem. 1983, 26, 431.
(20) Pandeya, S. N.; Sriram, D.; Nath, G.; De Clercq, E. Eur. J.
Pharm. Sci. 1999, 9, 25.
(21) Reddy, M. V. B.; Su, C.-R.; Chiou, W.-F.; Liu, Y.-N.; Chen, R.
Y.-H.; Bastow, K. F.; Lee, K.-H.; Wu, T.-S. Bioorg. Med. Chem. 2008,
16, 73587370.
(22) Karbe, H. Arch. Pharm. 1950, 283, 38.
(23) Thompson, B. B. J. Pharm. Sci. 1968, 57, 715.
(24) Gao, S.; Hu, M. Mini Rev. Med. Chem. 2010, 10, 550567.
(25) Crozier, A.; Jaganath, I. B.; Clifford, M. N. Nat. Prod. Rep. 2009,
26, 10011043.
(26) Galati, G.; OBrian, P. J. Free Radical Biol. Med. 2004, 37, 287
303.
(27) Attia, S. M. Oxid. Med. Cell Longev. 2010, 3, 238253.
(28) Leeson, P.; St-Gallay, S. Med. Chem. Commun. 2011, 2, 91105.
(29) Lovering, F.; Bikker, J.; Humblet, C. J. Med. Chem. 2009, 52,
67526756.
(30) Ritchie, T. J.; Macdonald, S. J. F. Drug Discovery Today 2009, 14,
10111020.
(31) Zhang, Z.; Zhang, L.; Guan, X.; Shen, Z.; Xing, G.; Fan, X.;
Zhou, Q. Liq. Cryst. 2010, 37, 6976.
(32) Powles, M. A.; Allocco, J.; Yeung, L.; Nare, B.; Liberator, P.;
Schmatz, D. Antimicrob. Agents Chemother. 2012, 56, 24142419.
(33) Walliker, D.; Quakyi, I. A.; Wellems, T. E.; McCutchan, T. F.;
Szarfman, A.; London, W. T.; Corcoran, L. M.; Burkot, T. R.; Carter,
R. Science 1987, 236, 16611666.
(34) Noedl, H.; Wongsrichanalai, C.; Wernsdorfer, W. H. Trends
Parasitol. 2003, 19, 175181.
(35) Burkot, T. R.; Williams, J. L.; Schneider, I. Trans R. Soc. Trop.
Med. Hyg. 1984, 78, 339341.
(36) Ponnudurai, T.; Leeuwenberg, A. D.; Meuwissen, J. H. Trop.
Geogr. Med. 1981, 33, 5054.
(37) Personal communication, Dr. L. Wiesner, University of Cape
Town, Cape Town, South Africa.
(38) Park, E.; Yang, Y. J.; Kwak, J. H.; Jung, Y. H.; Kang, S. C.; Kim,
I. S. Bioorg. Med. Chem. Lett. 2012, 22, 36533655.
(39) Van der Westhuizen, J. H.; Noreljaleel, A. E. M.; Bonnet, S. L.;
Wilhelm-Mouton, A. PCT Int. Appl. 2011, WO 211151789A2
20111208.
(40) Trager, W.; Jensen, J. B. Science 1976, 193, 673675.
(41) Makler, M. T.; Ries, J. M.; Williams, J. A.; Bancroft, J. E.; Piper,
R. C.; Gibbins, B. L.; Hinrichs, D. J. Am. J. Trop. Med. Hyg. 1993, 48,
739741.
(42) Mosmann, T. J. Immunol. Methods 1983, 65, 5563.

DOI: 10.1021/acs.jnatprod.5b00114
J. Nat. Prod. XXXX, XXX, XXXXXX